BiomX Statistics
Total Valuation
BiomX has a market cap or net worth of $3.55 million. The enterprise value is $4.35 million.
| Market Cap | 3.55M |
| Enterprise Value | 4.35M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BiomX has 2.67 million shares outstanding. The number of shares has increased by 235.32% in one year.
| Current Share Class | 2.67M |
| Shares Outstanding | 2.67M |
| Shares Change (YoY) | +235.32% |
| Shares Change (QoQ) | +296.08% |
| Owned by Insiders (%) | 3.77% |
| Owned by Institutions (%) | 3.41% |
| Float | 2.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.89 |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24, with a Debt / Equity ratio of 0.08.
| Current Ratio | 0.24 |
| Quick Ratio | 0.09 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -247.34% and return on invested capital (ROIC) is -59.03%.
| Return on Equity (ROE) | -247.34% |
| Return on Assets (ROA) | -42.35% |
| Return on Invested Capital (ROIC) | -59.03% |
| Return on Capital Employed (ROCE) | -124.63% |
| Weighted Average Cost of Capital (WACC) | 9.11% |
| Revenue Per Employee | $16,600 |
| Profits Per Employee | -$2.28M |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BiomX has paid $4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.17% in the last 52 weeks. The beta is 1.34, so BiomX's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -98.17% |
| 50-Day Moving Average | 1.82 |
| 200-Day Moving Average | 22.41 |
| Relative Strength Index (RSI) | 46.94 |
| Average Volume (20 Days) | 395,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BiomX had revenue of $332,000 and -$45.50 million in losses. Loss per share was -$109.54.
| Revenue | 332,000 |
| Gross Profit | 97,000 |
| Operating Income | -22.44M |
| Pretax Income | -45.49M |
| Net Income | -45.50M |
| EBITDA | -20.04M |
| EBIT | -22.44M |
| Loss Per Share | -$109.54 |
Balance Sheet
The company has $572,000 in cash and $1.37 million in debt, with a net cash position of -$793,000 or -$0.30 per share.
| Cash & Cash Equivalents | 572,000 |
| Total Debt | 1.37M |
| Net Cash | -793,000 |
| Net Cash Per Share | -$0.30 |
| Equity (Book Value) | 17.62M |
| Book Value Per Share | 3.46 |
| Working Capital | -7.76M |
Cash Flow
In the last 12 months, operating cash flow was -$18.15 million and capital expenditures -$4,000, giving a free cash flow of -$18.16 million.
| Operating Cash Flow | -18.15M |
| Capital Expenditures | -4,000 |
| Depreciation & Amortization | 2.40M |
| Net Borrowing | 615,000 |
| Free Cash Flow | -18.16M |
| FCF Per Share | -$6.79 |
Margins
| Gross Margin | 29.22% |
| Operating Margin | -6,759.34% |
| Pretax Margin | -13,700.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BiomX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -235.32% |
| Shareholder Yield | -235.32% |
| Earnings Yield | -920.32% |
| FCF Yield | -367.26% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 9, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Sep 9, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
BiomX has an Altman Z-Score of -14.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.32 |
| Piotroski F-Score | 1 |